New drug delivery system (NDDS) provides a therapeutic amount of drug to the specific site in the body to accomplish promptly and then maintain the desired drug concentration. The drug- delivery system should deliver drug at a rate control by the necessity of the body over a specified term of treatment. The novel drug delivery technologies enable to formulate the novel drug delivery devices by incorporating the drug molecules into new delivery systems, thus providing numerous therapeutic and commercial advantages.
North America New Drug Delivery Systems Market Segments Size & Growth:
North America new drug delivery systems market size is projected to reach approximately $XX billion by the end of 2024 with a CAGR of close to 9.0% from $XX billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Increase in individual therapy, Requirement of controlled release of drugs, Increasing understanding of drug metabolism per individual and so on. However, Competition, Product Recalls, Stringent Regulatory Guidelines, Stability issues are thereby hampering the market growth.
North America New Drug Delivery Systems Market Segments Share:
North America new drug delivery systems market is segmented into the mode of delivery which comprises of Pulmonary Drug Delivery Devices, Oral
Delivery Devices, Injectable Drug Delivery system and so on. Among the method of delivery, Injectable drug delivery segment dominated the North America New Drug Delivery Systems Market in 2018. By Mode of action, the market is segregated into Slow dissolving salts and complexes, Hydrodynamic pressure controlled system and so on. By Mode of administration, the market is segmented into Electroporation, Inhalation drug delivery system by nebuliser, Iontophoresis and so on. By Geography, US is leading the market in this category with 65 % of the market share in 2018 and is expected to continue the trend during the forecast period. The introduction of new delivery systems to an existing molecule will significantly improve its safety, efficacy and patient compliance. These factors are bound to substantially affect the North American market for new drug delivery systems.
North America New Drug Delivery Systems Market Trends:
- Mylan N.V. announced the U.S. launch of Estradiol Vaginal Cream USP, 0.01%, the first generic version of Allergan’s Estrace Cream. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in the treatment of vulvar and vaginal atrophy.
- Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, announced that the New Drug Application (NDA) for INVELTYSTM (KPI-121 1%), a topical twice-a-day product candidate for the treatment of inflammation and pain in patients who have undergone ocular surgery, has been accepted for review by the United States Food and Drug Administration (FDA).
North America New Drug Delivery Systems Market Research Report:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- The primary market players, such as
- Kala Pharmaceuticals
- Mylan Laboratories Inc.
- Abbott Laboratories
- Mersana Therapeutics
- Delpor
atrophy.
Kala Pharmaceuticals, Inc.,
